EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy

Myrna Luna-Gutiérrez iD, Pedro Cruz-Nova iD, Nallely Jiménez-Mancilla iD, Rigoberto Oros-Pantoja, Nancy Lara-Almazán iD, Clara Santos-Cuevas iD, Erika Azorín-Vega iD, Blanca Ocampo-García iD, Guillermina Ferro-Flores iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241512382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Myrna Luna-Gutiérrez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico. Hauptthemen laut MEDLINE: Radiopharmaceuticals, B7-H1 Antigen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Mexiquense de Ciencia y Tecnologia, “Consejo Mexiquense de Ciencia y Tecnología” (COMECyT), International Atomic Energy Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current cancer therapies focus on reducing immunosuppression and remodeling the tumor microenvironment to inhibit metastasis, cancer progression, and therapeutic resistance. Programmed death receptor 1 (PD-1) is expressed on immune T cells and is one of the so-called checkpoint proteins that can suppress or stop the immune response. To evade the immune system, cancer cells overexpress a PD-1 inhibitor protein (PD-L1), which binds to the surface of T cells to activate signaling pathways that induce immune suppression. This research aimed to synthesize PD-L1 inhibitory peptides (PD-L1-i) labeled with lutetium-177 (177Lu-DOTA-PD-L1-i) and actinium-225 (225Ac-HEHA-PD-L1-i) and to preclinically evaluate their potential as radiopharmaceuticals for targeted radiotherapy at the tumor microenvironment level. Using PD-L1-i peptide as starting material, conjugation with HEHA-benzene-SCN and DOTA-benzene-SCN was performed to yield DOTA-PD-L1-i and HEHA-PD-L1-I, which were characterized by FT-IR, UV-vis spectroscopy, and HPLC. After labeling the conjugates with 225Ac and 177Lu, cellular uptake in HCC827 cancer cells (PD-L1 positive), conjugate specificity evaluation by immunofluorescence, radiotracer effect on cell viability, biodistribution, biokinetics, and assessment of radiation absorbed dose in mice with in duced lung micrometastases were performed. 225Ac-HEHA-PD-L1-i and 177Lu-DOTA-PD-L1-i, obtained with radiochemical purities of 95 ± 3% and 98.5 ± 0.5%, respectively, showed in vitro and in vivo specific recognition for the PD-L1 protein in lung cancer cells and high uptake in HCC287 lung micrometastases (>30% ID). The biokinetic profiles of 177Lu-DOTA-PD-L1-i and 225Ac-DOTA-PD-L1-i showed rapid blood clearance with renal and hepatobiliary elimination and no accumulation in normal tissues. 225Ac-DOTA-PD-L1-i produced a radiation dose of 5.15 mGy/MBq to lung micrometastases. In the case of 177Lu-DOTA-PD-L1-i, the radiation dose delivered to the lung micrometastases was ten times (43 mGy/MBq) that delivered to the kidneys (4.20 mGy/MBq) and fifty times that delivered to the liver (0.85 mGy/MBq). Therefore, the radiotherapeutic PD-L1-i ligands of 225Ac and 177Lu developed in this research could be combined with immunotherapy to enhance the therapeutic effect in various types of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsB7-H1 AntigenMiceAnimalsTissue DistributionBenzeneNeoplasm MicrometastasisSpectroscopy, Fourier Transform InfraredTumor MicroenvironmentLutetiumCell Line, TumorHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

PD-L1 radioinhibitorsactinium-225lutetium-177targeted radiotherapy

Substanzen

RadiopharmaceuticalsB7-H1 AntigenBenzeneLutetium1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.
  • Cátedras, CONACyT, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.
  • Faculty of Medicine, Universidad Autónoma del Estado de México, Toluca 50180, Mexico.

ORCID-Profile: Myrna Luna-Gutiérrez, Pedro Cruz-Nova, Nallely Jiménez-Mancilla, Nancy Lara-Almazán, Clara Santos-Cuevas, Erika Azorín-Vega, Blanca Ocampo-García, Guillermina Ferro-Flores

Förderung

  • Consejo Mexiquense de Ciencia y Tecnologia
  • “Consejo Mexiquense de Ciencia y Tecnología” (COMECyT)
  • International Atomic Energy Agency

Zitieren

APA

Luna-Gutiérrez, M., Cruz-Nova, P., Jiménez-Mancilla, N., Oros-Pantoja, R., Lara-Almazán, N., Santos-Cuevas, C., Azorín-Vega, E., Ocampo-García, B., & Ferro-Flores, G. (2023). Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512382

Vancouver

Luna-Gutiérrez M, Cruz-Nova P, Jiménez-Mancilla N, Oros-Pantoja R, Lara-Almazán N, Santos-Cuevas C, et al. Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512382

BibTeX
@article{LunaGutirrez2023,
  author = {Luna-Gutiérrez, Myrna and Cruz-Nova, Pedro and Jiménez-Mancilla, Nallely and Oros-Pantoja, Rigoberto and Lara-Almazán, Nancy and Santos-Cuevas, Clara and Azorín-Vega, Erika and Ocampo-García, Blanca and Ferro-Flores, Guillermina},
  title = {Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241512382}
}
Kostenlos starten →